Jazz Pharmaceuticals' Record Revenue And Cancer Data Raise Durability Question [Yahoo! Finance]
Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ)
Last jazz pharmaceuticals plc - ordinary shares earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
jazzpharma.com
Company Research
Source: Yahoo! Finance
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Jazz Pharmaceuticals (NasdaqGS:JAZZ) reported record annual revenue in its latest results. The company resolved major legal issues tied to key products, extending their expected commercial lifespans. Late stage data indicated zanidatamab could become a new standard of care for HER2+ gastroesophageal cancer, with a launch anticipated in the second half of 2026. Jazz Pharmaceuticals focuses on neuroscience and oncology therapies, with a concentration in rare diseases. The recent combination of record revenue, cleared legal overhangs, and late stage oncology data puts multiple parts of the business in motion at the same time, which is unusual for a single reporting period. For you as an investor, the key question is how durable these developments might be for NasdaqGS:JAZZ over the next few years. The progress around zanidatamab and the extended lifespans of estab
Show less
Read more
Impact Snapshot
Event Time:
JAZZ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAZZ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAZZ alerts
High impacting Jazz Pharmaceuticals plc - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
JAZZ
News
- Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate [Yahoo! Finance]Yahoo! Finance
- Day One Biopharmaceuticals gains amid takeover speculation [Seeking Alpha]Seeking Alpha
- Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know [Yahoo! Finance]Yahoo! Finance
- Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? [Yahoo! Finance]Yahoo! Finance
- Why Jazz Pharmaceuticals (JAZZ) Is Up 10.4% After Record Q4 Sales But Full-Year Loss [Yahoo! Finance]Yahoo! Finance
JAZZ
Earnings
- 2/24/26 - Beat
JAZZ
Sec Filings
- 3/5/26 - Form 144
- 3/5/26 - Form 144
- 3/4/26 - Form 4
- JAZZ's page on the SEC website